Despite the controversy surrounding the thicket of regulatory requirements for approval of biosimilars in various markets, regulatory agencies and governments around the world are pushing for these products’ availability as part of their efforts to reduce healthcare costs. The advent of biosimilars thus appears to be inevitable. The only questions are when that occurs, and what the process will be for biosimilar drug developers to get their products to market. Download this recent article titled, “It’s a Matter of Time”
Learn more about:
How our experience and continued involvement with biosimilar drug developers give us a valuable perspective on what that process will be in the United States, Europe, and other key markets.
How outsourcing partners are advancing biosimilars in the United States, Europe, and other key markets.
Where biosimilars are headed including current challenges and future opportunities.